Labcorp (LH) stock
Health Care · Health Care Services
Labcorp (LH) is a Health Care Services company in the Health Care sector, headquartered in Burlington, North Carolina. As of October 23, 2026, LH closed at $328.95, a market capitalization of $26.68 billion, the 349th largest company in the S&P 500. Over the last twelve months it generated $14.35 billion in revenue (+6% year over year) and $1.16 billion in free cash flow. The stock trades at 27.2x trailing earnings and 16.6x forward earnings.
- 1-year total return: +17.0% (dividends reinvested)
- 5-year return: +7.4% a year
- 52-week range: $244.52 – $341.80
- Gross margin 28.9%, operating margin 12.2%
- Dividend yield: 0.88%
- FI Handbook report card: C+ across 10 metrics
- 45th largest of 60 Health Care stocks in the S&P 500
LH price chart
1Y price change: +15.8% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| LH | +8.2% | +32.1% | +17.0% | +19.8% | +7.4% | +11.3% | +7.7% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1990.
LH key statistics
- Market cap
- $26.7B
- #349 in S&P 500
- P/E (TTM)
- 27.2x
- Forward P/E
- 16.6x
- EPS (TTM)
- $12.09
- Revenue (TTM)
- $14.3B
- +6%
- Free cash flow
- $1.2B
- Gross margin
- 28.9%
- Operating margin
- 12.2%
- Return on equity
- 11.7%
- Dividend yield
- 0.88%
- 52-week range
- $244.52 – $341.80
- Beta
- 0.85
- Price / sales
- 1.9x
- EV / EBITDA
- 14.4x
- Debt / equity
- 0.79x
- Employees
- 71,000
LH report card
C+Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth5.8%C
- Gross margin28.9%C
- Operating margin12.2%C
- FCF margin8.1%C
- Return on equity11.7%C
- Net debt / EBITDA2.9xD
- Forward P/E16.6xB
- PEG ratio1.2xB
- Shareholder yield2.6%C
- Share count change / yr-6.0%A
Labcorp financials
Revenue went from $9.6B in fiscal 2016 to $14.0B in fiscal 2025, growing 4.3% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.6B | $10.3B | $11.3B | $11.6B | $14.0B | $13.1B | $11.9B | $12.2B | $13.0B | $14.0B |
| Gross profit | $2.9B | $3.1B | $3.2B | $3.3B | $5.0B | $5.0B | $3.7B | $3.4B | $3.6B | $4.0B |
| Operating income | $1.3B | $1.3B | $1.3B | $1.3B | $2.4B | $3.0B | $1.4B | $725.6M | $1.1B | $1.4B |
| Net income | $711.8M | $1.2B | $883.7M | $823.8M | $1.6B | $2.4B | $1.3B | $418.0M | $746.0M | $876.5M |
| EPS (diluted) | $5.86 | $10.15 | $7.40 | $7.17 | $13.64 | $24.39 | $13.97 | $4.77 | $8.84 | $10.46 |
| Free cash flow | $918.2M | $1.2B | $925.6M | $1.0B | $1.8B | $2.7B | $1.5B | $874.1M | $1.1B | $1.2B |
| Buybacks | $43.9M | $338.1M | $700.0M | $450.0M | $100.0M | $1.7B | $1.1B | $1.0B | $250.1M | $450.0M |
| Dividends paid | — | — | — | — | — | — | $195.2M | $254.0M | $243.1M | $240.7M |
| Diluted shares | 121.4M | 120.9M | 119.4M | 114.8M | 114.1M | 97.5M | 91.6M | 87.6M | 84.4M | 83.8M |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into LH?
A reverse DCF asks what growth the current price requires. With an enterprise value of $33.4B and $1.2B of trailing free cash flow, Labcorp needs to grow free cash flow about 19.9% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew -7.2% a year over the last five years.
P/E ratio history
Current 31.4x vs. median 17.8x (10th–90th percentile 14.2x–30.8x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
LH dividend
- Dividend yield
- 0.88%
- Annual dividend
- $2.88
- Years of increases
- —
- 5-yr dividend growth
- 33.2%
- per year
- Payout ratio
- 24%
- Payments per year
- 4
Regular dividends per share by calendar year; special dividends excluded. Current year omitted until complete.
LH analyst price targets
16 analysts' average 12-month target is $345.13 (+5% vs. $328.95). Targets range from $293.00 to $385.00. 72% rate it a buy.
LH earnings
Next report: October 28, 2026. Labcorp has beaten EPS estimates 8 quarters in a row. Last quarter's revenue was $3.7B (+6% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Jul 30, 2026 | $4.77 | $4.99 | +4.7% |
| Apr 30, 2026 | $4.12 | $4.25 | +3.3% |
| Feb 17, 2026 | $3.94 | $4.07 | +3.3% |
| Oct 28, 2025 | $4.14 | $4.18 | +1.0% |
| Jul 24, 2025 | $4.16 | $4.35 | +4.5% |
| Apr 29, 2025 | $3.73 | $3.84 | +2.8% |
| Feb 6, 2025 | $3.39 | $3.45 | +1.7% |
| Oct 24, 2024 | $3.49 | $3.50 | +0.2% |
Stocks like LH
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 CVS CVS Health | -1.07% | +19% | $119.5B | 24.6x | Compare |
 CI Cigna | -2.83% | +3% | $81.1B | 12.7x | Compare |
 DGX Quest Diagnostics | -0.57% | +34% | $26.7B | 24.1x | Compare |
 DVA DaVita | -1.32% | +43% | $11.7B | 15.5x | Compare |
 LLY Eli Lilly and | -2.54% | +56% | $1.1T | 42.7x | Compare |
 JNJ Johnson & Johnson | -1.42% | +40% | $635.1B | 40.0x | Compare |
 ABBV AbbVie | +0.16% | +29% | $504.8B | 80.7x | Compare |
 UNH UnitedHealth | -1.62% | +19% | $375.3B | 26.9x | Compare |
LH news
- LH vs. DHR: Which Stock Is the Better Value Option? · Oct 22, 2026
- Labcorp Declares Quarterly Dividend · Oct 21, 2026
- Sector Update: Healthcare Stocks Gain Late Afternoon · Oct 20, 2026
- OPKO Health to Sell Select BioReference Assets to Labcorp for $722M · Oct 16, 2026
- Labcorp (LH) Stock Looks In Step With Its Cash Flow Outlook · Oct 16, 2026
LH stock FAQ
What is LH's market cap?
Labcorp's market capitalization is $26.68 billion as of October 23, 2026, ranking 349th in the S&P 500.
What is LH's P/E ratio?
LH trades at a trailing price-to-earnings ratio of 27.2x and a forward P/E of 16.6x. Its median P/E over the period we track is 17.8x.
Does LH pay a dividend?
Yes. Labcorp pays $2.88 per share a year, a 0.88% yield. Dividends grew 33.2% a year over the last five years.
How much has LH stock returned?
Including reinvested dividends, LH returned +17.0% over one year, +7.4% a year over five years, +11.3% a year over ten years through October 23, 2026.
Is LH stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Labcorp must grow free cash flow about 20% a year for the next decade. Its free cash flow fell 7% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the LH price target?
16 analysts cover LH with an average 12-month price target of $345.12, +5% from the current price. 72% of them rate it a buy.
When does LH report earnings?
Labcorp is expected to report earnings on October 28, 2026. It has beaten EPS estimates 8 quarters in a row.
How many employees does Labcorp have?
Labcorp has about 71,000 full-time employees, or $202,085 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology